Skip to content
Medical Health Aged Care, National News Current Affairs


The Australian Dental Association 2 mins read
ICC Sydney Convention Centre where the Dental Congress is taking place next week.

14th September, 2023




OVER 5,000 DENTISTS from 130 countries will head to Sydney next week (September 24-27) for the largest dental event ever held in Australia.

The main oral health challenges facing both Australians and people all over the world will be tackled in a packed 4-day Scientific Programme of over 220 talks featuring top Australian and international clinicians. Key topics of interest to the media include:

* the effects of vaping on the mouth and the rest of the body including how it compares to smoking,

* the strength of evidence of the link between oral and systemic health and the impact of the traveling oral microbiome on other body systems, including mouth bacteria in pregnant women and adverse pregnancy outcomes,

* the correlation between sexual and domestic violence and poor oral health in women - and the vital role dentists have to play,

* Artificial Intelligence’s application in dentistry and what it means for patients,

* the latest in sleep apnoea reduction and prevention techniques which could save lives, and

* the close link between gum disease and mental health issues like anxiety and depression, and how one affects the other.

It’s the 109th year of this international conference inaugurated by the Fédération Dentaire Internationale (FDI), which is jointly hosted this year by the Australian Dental Association and FDI.

The event at the world-class International Convention Centre in the heart of Sydney, is the first ‘in person’ World Dental Congress in four years and is expected to net the NSW economy $31m in revenue.

There is also a huge multi-level Exhibition space filled with the latest dental devices and equipment from around the globe. Media are invited to attend both talks from the Scientific Programme and the Exhibition - access the Congress Scientific Programme here.   

Media wanting to interview clinicians about any of the above topics listed here or any others from the Scientific Programme, or to attend the Exhibition, are asked to register here. The ADA Media Advisor will then be in touch. More information about Congress media facilities can be found here.

Any questions, call the ADA’s Federal Media Advisor Jenny Barlass 0484 869 086 or email:

The ADA and FDI look forward to welcoming you.


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.